Request Demo

Last update 17 Mar 2026

Interferon Beta-1b

Last update 17 Mar 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Interferons

Synonyms

IFN-beta-Ser, Interferon Beta-1b (genetical recombination), Recombinant human interferon beta-1b

+ [16]

Target

Type I IFN Receptor

Action

agonists, modulators

Mechanism

IFNAR agonists(Interferon alpha/beta receptor agonists), Immunomodulators

Therapeutic Areas

Immune System DiseasesNervous System DiseasesOther Diseases

Active Indication

Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary ProgressiveMultiple Sclerosis

Inactive Indication

Acquired Immunodeficiency SyndromeAIDS-Related ComplexCardiomyopathies+ [1]

Originator Organization

Chiron Corp.

Active Organization

Bayer AG

Novartis Pharmaceuticals Corp.

Bayer HealthCare Pharmaceuticals, Inc.

+ [2]

Inactive Organization

Novartis Europharm Ltd.

License Organization

Novartis AG

Bayer Pharma AG

Population Health Research Institute

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (23 Jul 1993),

Multiple Sclerosis

RegulationAccelerated Approval (United States), Orphan Drug (Japan)

Structure/Sequence

Sequence Code 79593

Source: *****

Clinical Trials associated with Interferon Beta-1b

NCT06053749

/ Active, not recruitingNot Applicable

INFORM - Interferon-Beta Exposure in the 2nd and 3rd Trimester of Pregnancy - a Register-Based Drug Utilisation Study in Finland and Sweden

Observational data have suggested no increased risk of adverse pregnancy outcomes associated with exposure to interferon-beta (IFNB) before or during pregnancy. After the emergence of these data, the European Medicines Agency approved a label change for IFNB in September 2019, stating that use of IFNB during pregnancy may be considered, if clinically needed. However, limited data on pregnancies exposed in the 2nd and 3rd trimesters were observed.
INFORM is a secondary use of data drug utilisation study (DUS) to determine late pregnancy exposure (i.e. during the 2nd and 3rd trimester) to IFNB in Finland and Sweden, which will inform whether the number of exposed pregnancies is adequate to conduct a cohort study on adverse pregnancy outcomes, with a focus on late pregnancy exposure.
The number of pregnancies will be initially reported three years after the revised label implementation (September 2019) and will include data on pregnancies from 1996 in Finland and from 2005 in Sweden up through 31 December 2022. If the number of pregnancies is deemed adequate for conducting the cohort study on adverse pregnancy outcomes, this DUS will be finalised with the drug utilisation data accrued up through 31 December 2022. If the number of pregnancies until 31 December 2022 is deemed inadequate, this study may be continued and the primary and secondary objectives may be examined five years after the revised label implementation, including pregnancies until 31 December 2024.

Start Date20 Mar 2024

Sponsor / Collaborator

Bayer AG

[+3]

NCT04079088

/ WithdrawnPhase 2

A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Oral BIIB061 as Add-On Therapy to Interferon-Beta 1 or Glatiramer Acetate Therapies in Relapsing Multiple Sclerosis

The primary objectives of the study are to evaluate the safety of BIIB061 versus placebo in participants with Relapsing Multiple Sclerosis (RMS), and to evaluate the efficacy of BIIB061 to improve disability outcome versus placebo in participants with RMS.
The secondary objectives of the study are to evaluate the effects of BIIB061 versus placebo on brain magnetic resonance imaging (MRI) markers of remyelination and axon preservation in chronic Multiple Sclerosis lesions and to evaluate the effects of BIIB061 versus placebo on additional measures of improved disability outcome.

Start Date30 Jun 2021

Sponsor / Collaborator

Biogen, Inc.

NCT04356339

/ CompletedNot Applicable

US PROmyBETAapp2.0: Ascertaining Medication Usage and Patient-reported Outcomes (PROs) Via the myBETAapp™ in Patients With Multiple Sclerosis Treated With BETASERON® Using BETACONNECT™ Autoinjector

In this study researchers want to learn more about the medication usage behavior among multiple sclerosis (MS) patients treated with BETASERON using the myBETAapp. Multiple sclerosis (MS) is a disease in which the covering called "myelin" around the nerves of the central nervous system degenerate. MS is a lifelong disease therefore requiring continuous treatment to delay the disease progression and reduce the rate of relapse (the return of signs and symptoms of). BETASERON is an approved medicine used to reduce the relapse in patients with MS. It is injected into the tissue under the skin using BETACONNECT autoinjector, which automatically captures injection data including injection date, time, speed, and depth and uploads the data into paired myBETAapp. This allows patients to organize and track their progress and share the injection information with their physicians. The medication usage behavior to be collected in this study includes the elements to what extent
* taking medication matches the presciber's recommendation (adherence, compliance),
* treatment for the prescribed duration (persistence) is continued and
* injections were missed. Among MS patients treated with Betaferon using the myBETAapp the study will also collect information on the health-related quality of life , treatment satisfaction and satisfaction with treatment support.

Start Date24 Nov 2020

Sponsor / Collaborator

Bayer AG

100 Clinical Results associated with Interferon Beta-1b

100 Translational Medicine associated with Interferon Beta-1b

100 Patents (Medical) associated with Interferon Beta-1b

1,276

Literatures (Medical) associated with Interferon Beta-1b

17 Feb 2026·PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Natalizumab exacerbates astrocytopathy in NMOSD via blockade of endothelial VCAM1–astrocytic integrin α4 interaction

Article

Author: Xue, Xiaochang ; An, Zixuan ; Kang, Jingqi ; Gao, Rui ; Wen, Qing ; Cheng, Guo ; Zhang, Lei ; Ding, Xiaoli ; Li, Ke ; Gong, Ye ; Cui, Tingting ; Zhang, Yaling ; Yang, Luting ; Lin, Lan ; Dai, Luhang ; Zhang, Xin ; Li, Pei ; Zeng, Yuechen ; Yan, Yaping ; Feng, Zhe

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune inflammatory disorder of the central nervous system (CNS) that shares clinical features with multiple sclerosis (MS) but typically manifests with more severe symptoms. The presence of pathogenic IgG autoantibodies targeting aquaporin-4 (AQP4) channels on astrocytes serves as a highly specific biomarker that distinguishes NMOSD from MS. Unlike MS, NMOSD is characterized by profound astrocytic destruction and exhibits a distinct response to therapies. Notably, disease-modifying therapies (DMTs) effective in MS, including natalizumab, interferon-β, and fingolimod, not only fail to benefit NMOSD patients but may also exacerbate disease progression. The precise molecular mechanisms underlying this immunomodulator-induced exacerbation, however, remain not yet fully elucidated. Here, we demonstrate that natalizumab alleviated experimental autoimmune encephalomyelitis (EAE) while exacerbating the autoimmune astrocytopathy in an “EAE-NMOSD” mouse model, a phenomenon associated with a reduction in actively proliferating astrocytes. Through molecular and signaling pathway analyses, we identify that endothelial-derived vascular cell adhesion molecule 1 (VCAM1) activates astrocytes via integrin α4 signaling, thereby mitigating astrocytopathy in NMOSD-like mice. Furthermore, astrocyte-specific integrin α4 deficiency exacerbates astrocytopathy, and notably, natalizumab-induced disease exacerbation does not occur in integrin α4-conditional knockout (CKO) mice. Finally, pharmacological activation of astrocytes rescues natalizumab-induced damage and ameliorates demyelination in NMOSD-like mice. Collectively, our findings provide mechanistic gaps regarding the clinical phenomenon underlying natalizumab-induced NMOSD exacerbation and suggest astrocyte-targeted therapeutic strategies as a potential intervention for NMOSD.

01 Jan 2026·BRAIN BEHAVIOR AND IMMUNITY

Developing interferon-β as a safe in vivo experimental-medicine model of human inflammation

Article

Author: MacIver, Claire ; Szomolay, Barbara ; Periche-Tomas, Eva ; Underwood, Jonathan ; Jones, Simon ; Triantafilou, Kathy ; Harrison, Neil A ; Guy, Carol A ; Leach, Helena ; Bone, Claudia

BACKGROUND:

Inflammation is increasingly implicated in a wide range of neuropsychiatric and neurodegenerative disorders from depression to dementia. Compelling evidence for an inflammatory role in these disorders includes experimental-medicine studies with IFN-α and endotoxin, alongside therapeutic benefits observed with anti-cytokine agents.

AIM:

To develop and characterise a new, safe in-vivo mild inflammatory response that is titratable, elicits robust host sickness manifestations within an experimentally tractable timeframe, and has minimal cardiovascular effects, avoiding the requirement for continuous cardiac monitoring and ensuring applicability across diverse experimental contexts and participant groups, from the young to the elderly.

METHODS:

Using a randomized, blinded, placebo-controlled, repeated measures cross-over design, physiological, behavioural, cytokine, cellular and transcriptomic immune responses were collected from 30 healthy volunteers (15 young (18-34) and 15 older (60-75) years) on two separate occasions, once after 100 µg subcutaneous IFN-β (EXTAVIA®) and once after subcutaneous saline (placebo) injection.

RESULTS:

IFN-β increased ∼15-fold at 4 h and 9-fold at 6½ hours and rapidly induced anticipated increases in negative mood, tiredness, tension and sickness symptoms and reduced vigour (all p < 0.01) without serious side effects. It was associated with a modest increase in temperature (mean: +1.1C) and heart rate (mean: +11 bpm) but no change in blood-pressure or cardiovascular instability. IL-6, TNF-α, neutrophil to lymphocyte ratio and monocyte count all showed significant increases (all p < 0.05). Transcriptomic analyses confirmed activation of classical Interferon signalling pathways as well as Toll-like Receptor (TLR), Inflammasome, Pyroptosis, MyD88 and a variety of other host response pathways that have been implicated in the pathophysiology of neuropsychiatric or neurodegenerative disorders.

CONCLUSIONS:

IFN-β is a safe, robust new experimental model of mild inflammation that can be safely used to induce transient changes in systemic inflammation in healthy individuals from 18-75 years. Modulation of diverse immunological processes suggests it could be a valuable new experimental medicine tool across neuropsychiatric and neurodegenerative disorders.

01 Dec 2025·INFLAMMOPHARMACOLOGY

Multiple sclerosis pathophysiology: a comprehensive review of genetic, environmental, and immunological drivers

Review

Author: Najmuldeen, Hastyar H ; Mustafa, Fryad S ; Jalal, Paywast J ; Mohammed, Sewara J ; Al-Bajalan, Sarwer J ; Ghafoor, Dlzar D ; Zangana, Bahashty A ; Ahmad, Dlshad O ; Alghofaili, Fayez

Multiple sclerosis (MS) is a complex, chronic neuroinflammatory and neurodegenerative disorder of the central nervous system. This comprehensive review synthesizes evidence to argue that the paramount challenge in MS is bridging the disconnect between anti-inflammatory therapies and ineffective neuroprotective strategies, necessitating a dual-target approach. The paper discusses the crucial roles of genetic predisposition, highlighting the HLA-DRB1*15:01 allele and other non-HLA loci, and environmental triggers, such as Epstein-Barr virus infection, vitamin D deficiency, and smoking. We detail the dysregulation of both T-cells (Th1 and Th17 subsets) and B-cells in the autoimmune attack on myelin, as well as the intricate mechanisms of neurodegeneration, axonal damage, and the challenges of remyelination. The review also incorporates emerging insights into the role of the gut microbiome and epigenetic modifications, underscoring the necessity of an integrative model to understand MS pathogenesis. Ultimately, this review provides a foundational understanding of converging biological drivers of MS. Therapeutically, currently approved disease-modifying therapies (DMTs)-including interferon-β, glatiramer acetate, oral S1P modulators, fumarates, teriflunomide, cladribine, natalizumab, and anti-CD20 monoclonals-reduce relapse frequency and MRI activity but do not eliminate disability progression, particularly in progressive MS. Acute relapses are treated with high-dose corticosteroids, with plasma exchange reserved for steroid-refractory cases. We therefore argue that future success requires integrated strategies that couple sustained control of peripheral inflammation with CNS-intrinsic neuroprotection and remyelination. Therapeutically, modern disease-modifying therapies (interferon-β, glatiramer acetate, oral S1P modulators, fumarates, teriflunomide, cladribine, natalizumab, anti-CD20 monoclonals including ocrelizumab, ofatumumab, and ublituximab) reduce relapse rates and MRI activity yet do not consistently prevent disability progression-particularly in non-active progressive MS. Acute relapses are treated with high-dose corticosteroids; plasma exchange is reserved for steroid-refractory attacks. These realities motivate mechanism-informed strategies that pair sustained immune control with CNS-intrinsic neuroprotection and remyelination.

News (Medical) associated with Interferon Beta-1b

13 Jan 2026

·www.biopharmadive.com

What Sanofi’s multiple sclerosis troubles could mean for the space

Doctors have long been hamstrung in their efforts to help patients with multiple sclerosis, as many treatments only target the diseases highly variable symptoms.Despite the approval of the first disease-altering therapy Betaseron in 1993 and the other effective drugs followed, many patients still struggle with treatment resistance.And recently, the space was delivered another blow when a drug called tolebrutinib and developed by French pharmaceutical giant Sanofi flunked a critical late-stage trial.Drug developers have hoped that BTK inhibitors might be a step forward in treating the disease, especially for the relapsing-remitting form that waxes and wanes. BTK blockers target an enzyme involved in the bodys immune response, and theyve shown the ability to slow the onset of new brain lesions as well as reduce inflammation.But tolebrutinib stumbled in two studies in relapsing disease and, a few weeks ago, missed its mark primary progressive MS, leading the company to abandon the indication. Then, in late December, the FDA rebuffedSanofis approval attempt in the non-relapsing secondary progressive form of MS. In a rejection letter, FDA officials questioned whether the drugs benefits outweighed the potentially fatal liver risks associated with treatment, even considering patients limited options.The decision appeared to catch company officials by surprise. Houman Ashrafian, Sanofis executive vice president and head of research and development, said in a press release that the FDA decision was a significant and meaningful change in direction from the agencys earlier feedback, and that the company was now working to find a path forward.But will this turn of events mark the end for tolebrutinib? And what does this mean for other drugs in the category?A widening approach to MSOther BTK drugs are still moving through the clinic, including Roches fenebrutinib, which is now in phase 3 for both relapsing and primary progressive MS. The drug met its primary endpoint by significantly reducing the annualized relapse rate over 96 weeks compared with Sanofis Aubagio in the first of two phase 3 trials for relapsing MS, the company announced in November. The drug also hit the mark in a second phase 3 in primary progressive MS, showing it was on par with Ocrevus, the only approved drug for the condition, and might have an edge starting at 24 weeks.These unprecedented results suggest that fenebrutinib could potentially become a best-in-disease medicine, said Dr. Levi Garraway, Genentechs chief medical officer and head of global product development, in the written release.But fenebrutinib has also run into liver-related concerns. In 2023, the FDA levied a temporary partial clinical hold after some trial participants showed signs of drug-induced liver injury. Patients recovered after they stopped taking the drug, and the trial resumed. In the current studies, liver safety appeared consistent with earlier work.Zenas BioPharmais also evaluating a BTK inhibitor called orelabrutinibthat it licensed from Chinas InnoCare Pharma. Studies are ongoing in primary progressive and secondary progressive disease. The drug showed significant reductions in inflammation and in the development of new lesions compared with placebo in a mid-stage trial, and it has a similar tolerability profile to other BTK inhibitors, according to the company.Also in contention is Novartis remibrutinib, which was recently approved to treat an inflammatory skin condition called chronic spontaneous urticaria. An upcoming phase 3 trial could help expand this approval to include relapsing MS by testing how well it performs against Aubagio.BTK drugs are not the only emerging medications in the works. Other MS research is focused on repairing the damaged nerve coating in hopes of improving function, such as remyelination drugs like CNM-AU8, a drinkable solution that could help the body repair damaged myelin.Moderna, meanwhile, is testing an mRNA-1195 vaccine for the condition. The vaccine targets the Epstein-Barr virus, which lives in the body after the initial infection and is linked to MS risk. Researchers suspect that EBV activity or reactivation may contribute to disease activity in some patients.Other investigational treatments focus on reducing inflammation, such as the phase 3 small molecule, IMU-838 from Immunic Therapeutics.CAR T-cell therapy is another early-stage option being explored for MS and has shown some promise in early studies for autoimmune conditions, like lupus. '

Phase 3Clinical ResultDrug ApprovalVaccineImmunotherapy

02 Oct 2025

·www.drugs.com

Higher Ultraprocessed Food Intake Tied to Increased Multiple Sclerosis Disease Activity

THURSDAY, Oct. 2, 2025 -- Higher ultraprocessed food (UPF) intake is linked to increased inflammatory multiple sclerosis (MS) disease activity over two to five years of follow-up, according to a study presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis, held Sept. 24 to 26 in Barcelona, Spain. Gloria Dalla Costa, M.D., from Harvard University in Boston, and colleagues examined whether a validated metabolomic signature of UPF intake is associated with MS disease activity in patients with a first demyelinating event. The analysis included 451 patients with clinically isolated syndrome who were randomly assigned to receive interferon beta-1b or placebo and were followed for five years. The researchers found that during the study period, 208 patients converted to clinically definite MS. There was no difference in conversion status by UPF scores. There was an association seen between higher UPF scores and greater T1 hypointense lesion volume (β, 0.001) and lower Multiple Sclerosis Functional Composite scores (β, –0.194) at baseline. At five years, participants in the highest UPF quartile experienced more frequent relapses (top versus bottom quartile: adjusted risk ratio [aRR], 1.30; 95 percent confidence interval [CI], 1.06 to 1.59), a higher rate of new active lesions by two years (aRR, 1.08; 95 percent CI, 1.00 to 1.17), and a larger increase in T2 lesion volume by two years (β, 173.97 mm³), independent of other prognostic factors. "This pattern suggests ultraprocessed foods act as a chronic inflammatory accelerant rather than a disease trigger, amplifying existing inflammatory processes in MS rather than determining whether someone develops the disease in the first place," Costa said in a statement. Several authors disclosed ties to relevant organizations. Press Release More Information

Clinical Result

29 Aug 2025

·www.einpresswire.com

January - March 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Addyi (flibanserin) Drug hypersensitivity The "Contraindications", "Warnings and Precautions", "Adverse Reactions", and "Medication Guide" sections of the labeling were updated in September 2021 to include hypersensitivity reactions. Addyi labeling Glucagon-like peptide-1 (GLP-1) analogues Adlyxin (lixisenatide) Bydureon (exenatide) Bydureon BCise (exenatide) Byetta (exenatide) Ozempic (semaglutide) Rybelsus (semaglutide) Saxenda (liraglutide) Soliqua (insulin glargine and lixisenatide) Trulicity (dulaglutide) Victoza (liraglutide) Xultophy (insulin degludec and liraglutide) Drug-induced liver injury The "Adverse Reactions" section of the liraglutide and dulaglutide labeling was updated in June 2022 to include information about elevations of liver enzymes. Example: Trulicity labeling FDA determined that no action is necessary at the time for lixisenatide, exenatide, and semaglutide based on available information. Alcohol-based hand sanitizers Exposure via inhalation FDA determined that no action is necessary at the time based on available information. A FDA Drug Safety Communication was issued on June 16, 2021. Amlodipine and Levamlodipine Products Azor (amlodipine and olmesartan medoxomil ) Caduet (amlodipine besylate and atorvastatin calcium) Conjupri (levamlodipine maleate) Consensi (amlodipine besylate and celecoxib) Exforge (amlodipine and valsartan) Exforge HCT (amlodipine/valsartan and hydrochlorothiazide) Lotrel (amlodipine besylate and benazepril hydrochloride) Katerzia (amlodipine benzoate) Norvasc (amlodipine besylate) Prestalia (amlodipine besylate and perindopril arginine) Tribenzor (amlodipine besylate/olmesartan medoxomil and hydrochlorothiazide) Twynsta (amlodipine and telmisartan) Non-cardiogenic pulmonary edema FDA determined that no action is necessary at the time based on available information. Avonex (interferon beta-1a) Betaseron (interferon beta-1b) Extavia (interferon beta-1b) Plegridy (pegylated interferon beta-1a) Rebif (interferon beta-1a) Injection site abscess FDA is evaluating the need for regulatory action. Bavencio (avelumab) Imfinzi (durvalumab) Keytruda (pembrolizumab) Libtayo (cemiplimab-rwlc) Opdivo (nivolumab) Tecentriq (atezolizumab) Scleroderma FDA determined that no action is necessary at the time based on available information. Bavencio (avelumab) Imfinzi (durvalumab) Keytruda (pembrolizumab) Libtayo (cemiplimab-rwlc) Opdivo (nivolumab) Tecentriq (atezolizumab) Cholangitis sclerosing The "Adverse Reactions" section of the Keytruda (pembrolizumab) labeling was updated in August 2021 to include sclerosing cholangitis. Example: Keytruda labeling FDA determined that no action is necessary at the time for Bavencio (avelumab), Imfinzi (durvalumab), Libtayo (cemiplimab-rwlc), Opdivo (nivolumab), and Tecentriq (atezolizumab) based on available information. Chloroquine Generic products containing chloroquine Phospholipidosis The “Warnings” section of the labeling was updated in May 2022 to include information about phospholipidosis. Eliquis (apixaban) Pradaxa (dabigatran etexilate mesylate) Savaysa (edoxaban tosylate) Xarelto (ribaroxaban) Generic products containing dabigatran etexilate mesylate Generic products containing ribaroxaban Menorrhagia The “Use in Specific Populations” section was updated April 2021 to add language to describe the risk of clinically significant uterine bleeding in females of reproductive potential. Eliquis label Pradaxa label Savaysa label Xarelto label Depakote (divalproex sodium) Depakote ER (divalproex sodium) Stavzor (valproic acid) Generic products containing divalproex sodium Generic products containing valproic acid Tubulointerstitial nephritis The "Adverse Reactions" section of the labeling was updated in November 2021 to include tubulointerstitial nephritis. Example: Depakote labeling Dupixent (dupilumab) Alopecias FDA is evaluating the need for regulatory action. H.P. Acthar Gel (corticotropin) Anaphylactic and anaphylactoid responses The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in October 2021 to include anaphylaxis. Acthar Gel labeling H.P. Acthar Gel (corticotropin) Cardiac arrhythmias The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in October 2021 to include atrial fibrillations and palpitations. Acthar Gel labeling Ibrance (palbociclib) Kisqali (ribociclib) Kisqali Femara Co-Pack (letrozole and ribociclib) Verzenio (abemaciclib) Second primary malignancy FDA determined that no action is necessary at the time based on available information. Lynparza (olaparib) Drug-induced liver injury FDA determined that no action is necessary at the time based on available information. Ocrevus (ocrelizumab) Autoimmune colitis The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Medication Guide" sections of the labeling were updated in August 2022 to include colitis. Ocrevus labeling Poteligeo (mogamulizumab-kpkc) Acute kidney injury The "Warnings and Precautions" section of the labeling was updated in March 2022 to include glomerulonephritis. Poteligeo labeling Ravicti (glycerol phenylbutyrate) Product labeling issue regarding stability and instructions for administration The container label, carton label, "Medication Guide", and sections of the Prescribing Information ("Dosage and Administration" and "Patient Counseling Information") were updated in September 2021 to enhance the instructions for administration. Ravicti labeling Spravato (esketamine) Hypertensive crisis FDA determined that no action is necessary at the time based on available information. Tremfya (guselkumab) Device use errors resulting in possible missed or partial doses The Tremfya One Press Instructions for Use (IFU) and carton labeling was updated in June 2023 to mitigate medication errors, such as underdose or no dose delivered. Tremfya labeling Trulance (plecanatide) Drug hypersensitivity The “Adverse Reactions” section of the Trulance labeling was updated April 2021 to include skin itching, hives, and rash. Trulance Label Trulance (plecanatide) Vomiting The “Adverse Reactions” section of the Trulance labeling was updated April 2021 to include vomiting. Trulance Label Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

100 Deals associated with Interferon Beta-1b

External Link

KEGG	Wiki	ATC	Drug Bank
D00746	Interferon Beta-1b	L03AB08	DB00068

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Multiple Sclerosis, Relapsing-Remitting	European Union	Bayer AG	30 Nov 1995
Multiple Sclerosis, Relapsing-Remitting	Iceland	Bayer AG	30 Nov 1995
Multiple Sclerosis, Relapsing-Remitting	Liechtenstein	Bayer AG	30 Nov 1995
Multiple Sclerosis, Relapsing-Remitting	Norway	Bayer AG	30 Nov 1995
Multiple Sclerosis, Secondary Progressive	European Union	Bayer AG	30 Nov 1995
Multiple Sclerosis, Secondary Progressive	Iceland	Bayer AG	30 Nov 1995
Multiple Sclerosis, Secondary Progressive	Liechtenstein	Bayer AG	30 Nov 1995
Multiple Sclerosis, Secondary Progressive	Norway	Bayer AG	30 Nov 1995
Multiple Sclerosis	United States	Bayer HealthCare Pharmaceuticals, Inc.	23 Jul 1993

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple sclerosis relapse	Phase 3	Sweden	-	28 Feb 2007
Acquired Immunodeficiency Syndrome	Phase 3	United States	Bayer AG	31 Aug 2001
AIDS-Related Complex	Phase 3	United States	Bayer AG	31 Aug 2001
Cardiomyopathies	Phase 2	France	Bayer AG	01 Dec 2002
Cardiomyopathies	Phase 2	Germany	Bayer AG	01 Dec 2002
Cardiomyopathies	Phase 2	Italy	Bayer AG	01 Dec 2002
Cardiomyopathies	Phase 2	Poland	Bayer AG	01 Dec 2002
Cardiomyopathies	Phase 2	Spain	Bayer AG	01 Dec 2002
Cardiomyopathies	Phase 2	Sweden	Bayer AG	01 Dec 2002
Cardiomyopathies	Phase 2	United Kingdom	Bayer AG	01 Dec 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04356495 (COVERAGE, ERS2023)	Phase 2/3	COVID-19	225	Placebo	jwdmvwhbmp(rswpxyxzbs) = inhaled IFN-β-1b, but not inhaled ciclesonide nor placebo, was linked to a decrease in plasma H3Cit levels (p: 0.02). vlqeyswomt (hzvdsypomo ) View more	Positive	09 Sep 2023
				Inhaled IFN-β-1b
NCT04647695 (Pubmed)	Phase 2	COVID-19	-	Interferon beta-1b + Remdesivir	urytxxczra(gyxabddlnu) = uraihvrvsh cykhfbpauj (ejpqgdlmsb ) View more	Positive	28 Jun 2022
				Remdesivir	urytxxczra(gyxabddlnu) = zxdcgpsmol cykhfbpauj (ejpqgdlmsb ) View more
NCT00176592 (BECOME, CTgov)	Phase 4	Multiple Sclerosis \| Multiple Sclerosis, Relapsing-Remitting	75	Betaseron (Betaseron)	zvfammzrrx(bxxleiuqxs) = ywwrakufdu qwrqtjnoez (uhmygqmkuy, 2.76) View more	-	16 Nov 2021
				Copaxone (Copaxone)	zvfammzrrx(bxxleiuqxs) = ytmpcuzysc qwrqtjnoez (uhmygqmkuy, 2.46) View more
NCT00787657 (Pubmed \| BMC Neurol)	Not Applicable	Multiple Sclerosis	481	interferon beta-1b (41-50 years)	qkcdcitbpj(qyjlhvpweu) = The percentage of patients with anxiety and depression, as measured by HADS, were stable over the study period ketngatrqf (xynxokidfz )	-	23 Aug 2021
				interferon beta-1b (> 50 years)
ECTRIMS2020	Not Applicable	COVID-19 SARS-CoV-2	109	IFN β-1b	jlzlqwtyug(cgxjafgprp) = mxnhquhwvb avsmkzqbtr (gngkxahgph ) View more	-	07 Dec 2020
NCT03134573 (Pubmed \| J Med Internet Res)	Not Applicable	Multiple Sclerosis	96	Interferon Beta-1b (Patients using myBETAapp)	uspkgzbdft(uougxwexep) = fhvlbljiud tvuuqlvmuz (ruysmxxkgz ) View more	-	29 Jul 2019
NCT00185211 (BENEFIT, EAN2019)	Phase 3	MRI lesions	261	Interferon beta-1b (early treatment)	hukfjjpxec(vapxdghrha) = fxirrquagi osjbdupokq (boltptmqrs ) View more	Positive	27 Jun 2019
BENEFIT 15 (AAN2019)	Phase 3	Carcinoma in situ of uterine cervix	468	Interferon beta-1b (early treatment)	czbecwsaiq(jiwdzfytoc) = 0.2083 overall over 15 years tgqudgsoml (klceifbjrx ) View more	Positive	09 Apr 2019
ECTRIMS2018	Not Applicable	Multiple Sclerosis, Relapsing-Remitting	1,866	disease modifying therapies (DMTs) (Patients aged 18-30)	uventfgcqp(atwuowxjal) = xxgbbnrjfc qddgxdoyng (wrtwecjdtw )	Positive	09 Oct 2018
				disease modifying therapies (DMTs) (All ages)	uventfgcqp(atwuowxjal) = nwizwnkkwe qddgxdoyng (wrtwecjdtw )
AAN2017	Not Applicable	-	-	Interferon beta-1b	ufxzjvyhfi(xmznhltovi) = nxicyeatro wyxlcsgpvk (ontrdmxygj ) View more	-	18 Apr 2017

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis